<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>The heavy chain diseases</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">The heavy chain diseases</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">The heavy chain diseases</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">S Vincent Rajkumar, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ann S LaCasce, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rebecca F Connor, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 07, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The heavy chain diseases (HCDs) are rare B cell proliferative disorders characterized by the production of a monoclonal (M) protein consisting of a portion of the immunoglobulin heavy chain without a bound light chain [<a href="#rid1">1-6</a>]. The heavy chain in HCD is often incomplete or truncated and a sharp, localized peak may not be seen on the electrophoretic tracing of serum or urine.</p><p>The HCDs will be reviewed here. Heavy chain deposition disease is a different disorder that is discussed in detail elsewhere, in which abnormal heavy chains or short (truncated) heavy chains cause fibrillar or granular tissue deposits. (See  <a class="medical medical_review" href="/z/d/html/6665.html" rel="external">"Monoclonal immunoglobulin deposition disease"</a> and  <a class="medical medical_review" href="/z/d/html/6666.html" rel="external">"Treatment and prognosis of immunoglobulin light chain (AL) amyloidosis"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">OVERVIEW</span><span class="headingEndMark"> — </span>Three types of HCDs are recognized, based on the class of immunoglobulin heavy chain produced (eg, alpha, gamma, mu) by the malignant cell [<a href="#rid3">3,5,6</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Alpha HCD is a form of extranodal marginal zone lymphoma of mucosa associated lymphoid tissue (MALT) that is also called immunoproliferative small intestinal disease (IPSID), Mediterranean lymphoma, or Seligmann disease. (See <a class="local">'Alpha HCD'</a> below and  <a class="medical medical_review" href="/z/d/html/4743.html" rel="external">"Clinical presentation and diagnosis of primary gastrointestinal lymphomas", section on 'Lymphoma of the small intestine'</a> and  <a class="medical medical_review" href="/z/d/html/4733.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of extranodal marginal zone lymphoma of mucosa associated lymphoid tissue (MALT)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Gamma HCD (Franklin's disease) is typically associated with the presence of a systemic lymphoma, often of mixed lymphoid-plasmacytic character. (See <a class="local">'Gamma HCD'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mu HCD has clinical features resembling small lymphocytic lymphoma/chronic lymphocytic leukemia, often with distinctive vacuolated lymphocytes/plasma cells in the bone marrow. (See <a class="local">'Mu HCD'</a> below.)</p><p></p><p>Prognosis of the HCDs is variable, and no standardized effective treatment programs are available except for alpha-HCD, which in its early stage may respond to antibiotics [<a href="#rid2">2</a>]. (See <a class="local">'Alpha HCD'</a> below.)</p><p class="headingAnchor" id="H3"><span class="h1">PATHOPHYSIOLOGY</span></p><p class="headingAnchor" id="H4"><span class="h2">The normal immunoglobulin molecule</span><span class="headingEndMark"> — </span>The immunoglobulin molecule is composed of two heavy and two light chains, joined by disulfide bonds  (<a class="graphic graphic_figure graphicRef56393" href="/z/d/graphic/56393.html" rel="external">figure 1</a>). The normal heavy chain constant region (CH region) has a number of domains, of which CH1 is responsible for light chain binding. In the absence of an associated light chain, the CH1 domain binds to heat shock protein 78 (heavy chain binding protein, BiP), and the heavy chain undergoes proteasomal degradation rather than secretion [<a href="#rid7">7</a>]. As a result, normal heavy chains without light chains are not detected in the serum. (See  <a class="medical medical_review" href="/z/d/html/3971.html" rel="external">"Structure of immunoglobulins", section on 'Structure'</a>.)</p><p class="headingAnchor" id="H5"><span class="h2">The abnormal heavy chain in HCD</span><span class="headingEndMark"> — </span>In the HCDs, noncontiguous deletions in the switch-CH1 region prevent binding of the abnormal heavy chain to light chains as well as to heat shock protein 78, thereby avoiding proteasomal degradation [<a href="#rid8">8-10</a>]. The heavy chains are then secreted into the plasma (or jejunal fluid in the case of alpha HCD) and, if small enough, may appear in the urine.</p><p class="headingAnchor" id="H6"><span class="h2">Making the diagnosis</span><span class="headingEndMark"> — </span>A patient with one of the HCDs will come to the attention of clinicians in two different ways:</p><p class="bulletIndent1"><span class="glyph">●</span>For consideration of the diagnosis of a localized or diffuse lymphomatous process and/or:</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For evaluation of the presence of a monoclonal protein in the serum, urine, or tissues (see  <a class="medical medical_review" href="/z/d/html/6655.html" rel="external">"Laboratory methods for analyzing monoclonal proteins", section on 'Causes'</a>)</p><p></p><p>The specific diagnosis of one of the HCDs, along with the diagnosis of the underlying plasma cell/lymphocytic clonal disorder, can be made via a combination of studies of tissues and analysis of serum or urine samples.</p><p class="headingAnchor" id="H7"><span class="h3">Tissue diagnosis</span><span class="headingEndMark"> — </span>Immunohistochemical staining of an affected tissue (eg, mass lesion, enlarged lymph node(s), bone marrow involvement, hepatosplenomegaly) shows the presence of a clonal population of cells staining positively for a heavy chain but negative for both kappa and lambda light chains.</p><p class="headingAnchor" id="H8"><span class="h3">Serum and urine studies</span><span class="headingEndMark"> — </span>The frequency of finding a monoclonal "spike" on serum or urine protein electrophoresis is variable, and differs among the three types of HCD. On immunofixation, the abnormal protein, if present, consists of a heavy chain (ie, alpha, gamma, mu) without an associated light chain. (See  <a class="medical medical_review" href="/z/d/html/6655.html" rel="external">"Laboratory methods for analyzing monoclonal proteins", section on 'False negative results'</a>.)</p><p>As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>In alpha HCD, there is not a distinct band or sharp peak on electrophoresis, presumably because of the tendency of these chains to form polymers of different sizes. In some patients, the abnormal proteins are found in jejunal fluid but not in the serum. (See  <a class="medical medical_review" href="/z/d/html/4743.html" rel="external">"Clinical presentation and diagnosis of primary gastrointestinal lymphomas", section on 'Lymphoma of the small intestine'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In gamma HCD, the electrophoretic tracing may appear broad and heterogeneous rather than showing a localized band.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In mu HCD, panhypogammaglobulinemia is a prominent feature and a localized band is found in only 40 percent.</p><p></p><p>While not routinely available, some cases of heavy chain disease have been identified using mass spectrometry (MS) [<a href="#rid11">11</a>]. MS and other laboratory methods for analyzing monoclonal proteins in the serum and urine are discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/6655.html" rel="external">"Laboratory methods for analyzing monoclonal proteins", section on 'False negative results'</a>.)</p><p class="headingAnchor" id="H9"><span class="h1">ALPHA HCD</span><span class="headingEndMark"> — </span>Alpha HCD (also called immunoproliferative small intestinal disease [IPSID], Mediterranean lymphoma, Seligmann disease) is a form of extranodal marginal zone lymphoma (EMZL) of mucosa associated lymphoid tissue (MALT), with the same histologic features of gastric EMZL with marked plasma cell differentiation. It is the most common form of HCD and occurs in patients from the Mediterranean region or Middle East, usually young males, and is often associated with relatively poor sanitation. (See  <a class="medical medical_review" href="/z/d/html/4743.html" rel="external">"Clinical presentation and diagnosis of primary gastrointestinal lymphomas", section on 'Lymphoma of the small intestine'</a>.)</p><p>Issues related to alpha HCD are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/4743.html" rel="external">"Clinical presentation and diagnosis of primary gastrointestinal lymphomas", section on 'Lymphoma of the small intestine'</a>.)</p><p>Summarized briefly, the gastrointestinal tract is involved in alpha HCD, resulting in abdominal pain, severe malabsorption with chronic diarrhea, steatorrhea, and loss of weight. Growth retardation (in children), digital clubbing, and mesenteric lymphadenopathy may also be present.</p><p>Infiltration of the jejunal mucosa with plasmacytoid cells is the most frequent pathologic feature. The duodenum and ileum are less often affected. The diagnosis depends on the recognition of a monoclonal alpha heavy chain without an associated light chain in the serum, urine, intestinal secretions, or cells infiltrating the intestinal mucosa.</p><p>The serum protein electrophoretic pattern is normal in one-half of cases, and in the remainder an unimpressive broad band may appear in the alpha-2 or beta mobility regions. The amount of alpha heavy chain in the urine is small.</p><p>In the absence of therapy, alpha HCD typically is progressive and fatal. The usual treatment is with antibiotics such as tetracyclines and eradication of any concurrent infection (eg, parasites, viruses, <em>Helicobacter pylori</em>, <em>Campylobacter jejuni</em>) [<a href="#rid12">12,13</a>]. Patients who do not respond adequately to antibiotics are treated with therapies directed at the marginal zone lymphoma, which may include chemotherapy, <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, and/or involved-site radiation therapy. (See  <a class="medical medical_review" href="/z/d/html/4733.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of extranodal marginal zone lymphoma of mucosa associated lymphoid tissue (MALT)", section on 'Campylobacter jejuni'</a> and  <a class="medical medical_review" href="/z/d/html/4710.html" rel="external">"Treatment of extranodal marginal zone lymphoma of mucosa associated lymphoid tissue (MALT lymphoma)", section on 'Small intestine MZL'</a>.)</p><p class="headingAnchor" id="H10"><span class="h1">GAMMA HCD</span><span class="headingEndMark"> — </span>Patients with gamma HCD typically present with systemic symptoms, lymphadenopathy, splenomegaly, and/or anemia, and occasionally with palatal and uvular swelling [<a href="#rid1">1,14</a>]. The median age of patients with gamma HCD is 60 to 70 years, although the condition has been noted in persons younger than age 20.</p><p>In one of the largest reported series of 23 patients with gamma HCD seen at the Mayo Clinic, the following findings were present [<a href="#rid14">14</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Monoclonal spike on electrophoresis – 83 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Lymphadenopathy – 35 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Hemoglobin &lt;10 g/dL – 35 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Bone marrow involvement – 32 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Splenomegaly – 30 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Skin involvement – 30 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Platelet count &lt;100,000/microL – 17 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Hepatomegaly – 4 percent</p><p></p><p>The clinical findings ranged from an asymptomatic state (eg, monoclonal gammopathy of undetermined significance, MGUS) to an aggressive lymphoproliferative process.</p><p>Autoimmune manifestations are seen in about one-third of patients (eg, idiopathic thrombocytopenia purpura, hemolytic anemia, vasculitis, systemic lupus erythematosus, rheumatoid arthritis) [<a href="#rid1">1,3,14,15</a>].</p><p>Gamma HCD is typically associated with a polymorphous infiltrate, including admixtures of lymphocytes, plasmacytoid lymphocytes, plasma cells, immunoblasts, and eosinophils [<a href="#rid1">1,3,16,17</a>].</p><p>The electrophoretic pattern often shows a broad-based band more suggestive of a polyclonal increase but the gamma chains are monoclonal. The diagnosis is established by immunofixation, which shows that the abnormal protein consists only of gamma heavy chains without associated light chains. The monoclonal gamma chains have significant deletions of amino acids, including the CH1 domain of the constant region.</p><p>Treatment is indicated <strong>only</strong> for symptomatic patients. There is only anecdotal experience with any regimen for the treatment of this disease. Options include <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">doxorubicin</a>, <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">vincristine</a>, and <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> (CHOP regimen)  (<a class="graphic graphic_table graphicRef66136" href="/z/d/graphic/66136.html" rel="external">table 1</a>) or, if the abnormal cells express CD20, the anti-CD20 antibody <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> plus CHOP (R-CHOP)  (<a class="graphic graphic_table graphicRef63586" href="/z/d/graphic/63586.html" rel="external">table 2</a>), or myeloma regimens such as cyclophosphamide, <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a>, <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> (CyBorD) [<a href="#rid2">2,3,14,18-20</a>].</p><p>The prognosis of gamma HCD is variable and ranges from the asymptomatic presence of a stable monoclonal heavy chain in the serum or urine (eg, MGUS) to a rapidly progressive downhill course of a few weeks duration (eg, highly aggressive lymphoma). In the Mayo Clinic series, the median survival was 7.4 years with an extremely wide range (1 month to more than 21 years) [<a href="#rid14">14</a>].</p><p class="headingAnchor" id="H11"><span class="h1">MU HCD</span><span class="headingEndMark"> — </span>Mu HCD is the least common of the HCDs and is characterized by a monoclonal mu chain fragment in the serum. It has features resembling chronic lymphocytic leukemia/small lymphocytic lymphoma (eg, anemia, hepatosplenomegaly), although peripheral adenopathy is less common than in CLL [<a href="#rid1">1</a>]. Osteolytic lesions or pathologic fractures have been reported in occasional patients. Unlike alpha and gamma HCD, some patients with mu HCD have increased free light chain secretion (Bence Jones proteinuria), and may develop cast nephropathy or amyloidosis [<a href="#rid21">21,22</a>].</p><p>Common features include characteristic vacuolated plasma cells or lymphoid cells in the bone marrow and panhypogammaglobulinemia [<a href="#rid2">2,18,23</a>]. The serum protein electrophoretic pattern is usually normal except for hypogammaglobulinemia.</p><p>The course of mu HCD is variable, and survival ranges from a few months to many years. Asymptomatic patients are observed without therapy, while symptomatic patients are treated similar to patients with non-Hodgkin lymphoma. There is only anecdotal experience with any regimen for the treatment of this disease. Reported treatment has included <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> (if the tumor expresses CD20) with or without chemotherapy regimens used for indolent non-Hodgkin lymphomas. The regimen is selected to mimic that of the lymphoma that the tumor most closely mimics.  </p><p class="headingAnchor" id="H12"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definitions</strong> – The heavy chain diseases (HCD) are rare B cell proliferative disorders characterized by the production of a monoclonal (M) protein consisting of a portion of the immunoglobulin heavy chain without a bound light chain. The heavy chain is often incomplete or truncated and a sharp, localized peak may not be seen on the electrophoretic tracing of serum or urine. (See <a class="local">'The abnormal heavy chain in HCD'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong> – The clinical presentation of the HCDs is that of a patient with a low grade B cell malignancy.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Alpha HCD – The gastrointestinal tract is most commonly involved in alpha-HCD, resulting in abdominal pain, malabsorption with chronic diarrhea, steatorrhea, and loss of weight. Infiltration of the jejunal mucosa with plasmacytoid cells is the most frequent pathologic feature. The diagnosis depends on the recognition of a monoclonal alpha heavy chain without an associated light chain in the serum, urine, intestinal secretions, or the cells infiltrating the intestinal mucosa. (See <a class="local">'Alpha HCD'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Gamma HCD – Patients with gamma HCD most often present with systemic symptoms, lymphadenopathy, hepatosplenomegaly, and anemia, and occasionally with palatal and uvular swelling. Autoimmune manifestations are seen in about one-third of patients. Gamma HCD is typically associated with a polymorphous infiltrate, including admixtures of lymphocytes, plasmacytoid lymphocytes, plasma cells, immunoblasts, and eosinophils. The abnormal protein consists only of gamma heavy chains without an associated light chain. (See <a class="local">'Gamma HCD'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Mu HCD – Mu chain HCD has features resembling chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL; eg, anemia, hepatosplenomegaly), although peripheral adenopathy is less commonly seen than in CLL. Vacuolated lymphocytes/plasma cells in the bone marrow and panhypogammaglobulinemia are commonly seen. The abnormal protein consists only of mu heavy chains without an associated light chain. (See <a class="local">'Mu HCD'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of one of the HCDs can be made on histopathologic examination of affected tissues and/or analysis of serum or urine samples by electrophoresis and immunofixation. A typical monoclonal "spike" in the serum or urine may not always be present. On serum or urine immunofixation or immunohistochemical staining of affected tissues, the abnormal protein consists of a heavy chain (ie, alpha, gamma, mu) without an associated light chain. (See <a class="local">'Making the diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – Reports concerning the treatment of the HCDs are largely anecdotal. Accordingly, with the exception of initial treatment of alpha HCD with appropriate antibiotics, which can be curative in some cases, all of the recommendations given below are based on low quality evidence.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Alpha HCD – We recommend eradication of any concurrent infection (eg, parasites, viruses, <em>Helicobacter pylori</em>, <em>Campylobacter jejuni</em>) with appropriate antibiotics as initial treatment of alpha HCD (<a class="grade" href="https:///uptodate/show/grade_3" rel="external">Grade 1C</a>). (See <a class="local">'Alpha HCD'</a> above.)</p><p></p><p class="bulletIndent2">For those with symptomatic disease who do not respond adequately to antibiotics, chemotherapy similar to that used to treat non-Hodgkin lymphoma is most appropriate.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Gamma HCD – Treatment is indicated <strong>only</strong> for symptomatic patients. There is only anecdotal experience with any regimens. Options include <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">vincristine</a>, and <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a>, with or without <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">doxorubicin</a> (eg, the CHOP regimen)  (<a class="graphic graphic_table graphicRef66136" href="/z/d/graphic/66136.html" rel="external">table 1</a>), or, if the abnormal cells express CD20, the anti-CD20 antibody <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, or myeloma regimens such as cyclophosphamide, <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a>, <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> (CyBorD). (See <a class="local">'Gamma HCD'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Mu HCD – Treatment for symptomatic patients with mu HCD is similar to that employed in patients with non-Hodgkin lymphoma. (See <a class="local">'Mu HCD'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Grogan TM, Van Camp B, Kyle RA, et al. Plasma cell neoplasms. In: World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, Jaffe ES, Harris NL, Stein H, Vardiman JW (Eds), IARC Press, Lyon 2001. p.142.</li><li><a class="nounderline abstract_t">Wahner-Roedler DL, Kyle RA. Heavy chain diseases. Best Pract Res Clin Haematol 2005; 18:729.</a></li><li><a class="nounderline abstract_t">Munshi NC, Digumarthy S, Rahemtullah A. Case records of the Massachusetts General Hospital. Case 13-2008. A 46-year-old man with rheumatoid arthritis and lymphadenopathy. N Engl J Med 2008; 358:1838.</a></li><li><a class="nounderline abstract_t">Corcos D, Osborn MJ, Matheson LS. B-cell receptors and heavy chain diseases: guilty by association? Blood 2011; 117:6991.</a></li><li><a class="nounderline abstract_t">Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016; 127:2375.</a></li><li class="breakAll">World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Swerdlow SH, Campo E, Harris NL, et al. (Eds), IARC Press, Lyon 2008.</li><li><a class="nounderline abstract_t">Haas IG, Wabl M. Immunoglobulin heavy chain binding protein. Nature 1983; 306:387.</a></li><li><a class="nounderline abstract_t">Alexander A, Anicito I, Buxbaum J. Gamma heavy chain disease in man. Genomic sequence reveals two noncontiguous deletions in a single gene. J Clin Invest 1988; 82:1244.</a></li><li><a class="nounderline abstract_t">Hendershot L, Bole D, Köhler G, Kearney JF. Assembly and secretion of heavy chains that do not associate posttranslationally with immunoglobulin heavy chain-binding protein. J Cell Biol 1987; 104:761.</a></li><li><a class="nounderline abstract_t">Prelli F, Frangione B. Franklin's disease: Ig gamma 2 H chain mutant BUR. J Immunol 1992; 148:949.</a></li><li><a class="nounderline abstract_t">Thoren KL, Eveillard M, Chan P, et al. Identification of gamma heavy chain disease using MALDI-TOF mass spectrometry. Clin Biochem 2020; 77:57.</a></li><li><a class="nounderline abstract_t">Tracy RP, Kyle RA, Leitch JM. Alpha heavy-chain disease presenting as goiter. Am J Clin Pathol 1984; 82:336.</a></li><li><a class="nounderline abstract_t">Evangelista-Leite D, Affonso Madaloso B, Shouta Yamashita B, et al. Treating chronic diarrhea: A systematic review on Immunoproliferative Small Intestinal Disease (IPSID). PLoS One 2021; 16:e0253695.</a></li><li><a class="nounderline abstract_t">Wahner-Roedler DL, Witzig TE, Loehrer LL, Kyle RA. Gamma-heavy chain disease: review of 23 cases. Medicine (Baltimore) 2003; 82:236.</a></li><li><a class="nounderline abstract_t">Husby G, Blichfeldt P, Brinch L, et al. Chronic arthritis and gamma heavy chain disease: coincidence or pathogenic link? Scand J Rheumatol 1998; 27:257.</a></li><li><a class="nounderline abstract_t">FRANKLIN EC. STRUCTURAL STUDIES OF HUMAN 7S GAMMA-GLOBULIN (G IMMUNOGLOBULIN). FURTHER OBSERVATIONS OF A NATURALLY OCCURRING PROTEIN RELATED TO THE CRYSTALLIZABLE (FAST) FRAGMENT. J Exp Med 1964; 120:691.</a></li><li><a class="nounderline abstract_t">Fermand JP, Brouet JC. Heavy-chain diseases. Hematol Oncol Clin North Am 1999; 13:1281.</a></li><li><a class="nounderline abstract_t">Wahner-Roedler DL, Kyle RA. Mu-heavy chain disease: presentation as a benign monoclonal gammopathy. Am J Hematol 1992; 40:56.</a></li><li><a class="nounderline abstract_t">Agrawal S, Abboudi Z, Matutes E, Catovsky D. First report of fludarabine in gamma-heavy chain disease. Br J Haematol 1994; 88:653.</a></li><li><a class="nounderline abstract_t">Bianchi G, Anderson KC, Harris NL, Sohani AR. The heavy chain diseases: clinical and pathologic features. Oncology (Williston Park) 2014; 28:45.</a></li><li><a class="nounderline abstract_t">Preud'homme JL, Bauwens M, Dumont G, et al. Cast nephropathy in mu heavy chain disease. Clin Nephrol 1997; 48:118.</a></li><li><a class="nounderline abstract_t">Kinoshita K, Yamagata T, Nozaki Y, et al. Mu-heavy chain disease associated with systemic amyloidosis. Hematology 2004; 9:135.</a></li><li><a class="nounderline abstract_t">Zucker-Franklin D, Franklin EC. Ultrastructural and immunofluorescence studies of the cells associated with mu-chain disease. Blood 1971; 37:257.</a></li></ol></div><div id="topicVersionRevision">Topic 6645 Version 17.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Grogan TM, Van Camp B, Kyle RA, et al. Plasma cell neoplasms. In: World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, Jaffe ES, Harris NL, Stein H, Vardiman JW (Eds), IARC Press, Lyon 2001. p.142.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16026747" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Heavy chain diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18434654" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Case records of the Massachusetts General Hospital. Case 13-2008. A 46-year-old man with rheumatoid arthritis and lymphadenopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21508409" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : B-cell receptors and heavy chain diseases: guilty by association?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26980727" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The 2016 revision of the World Health Organization classification of lymphoid neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26980727" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The 2016 revision of the World Health Organization classification of lymphoid neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6417546" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Immunoglobulin heavy chain binding protein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3139711" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Gamma heavy chain disease in man. Genomic sequence reveals two noncontiguous deletions in a single gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3102505" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Assembly and secretion of heavy chains that do not associate posttranslationally with immunoglobulin heavy chain-binding protein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1730882" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Franklin's disease: Ig gamma 2 H chain mutant BUR.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31884198" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Identification of gamma heavy chain disease using MALDI-TOF mass spectrometry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6431799" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Alpha heavy-chain disease presenting as goiter.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34270561" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Treating chronic diarrhea: A systematic review on Immunoproliferative Small Intestinal Disease (IPSID).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12861101" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Gamma-heavy chain disease: review of 23 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9751465" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Chronic arthritis and gamma heavy chain disease: coincidence or pathogenic link?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14247713" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : STRUCTURAL STUDIES OF HUMAN 7S GAMMA-GLOBULIN (G IMMUNOGLOBULIN). FURTHER OBSERVATIONS OF A NATURALLY OCCURRING PROTEIN RELATED TO THE CRYSTALLIZABLE (FAST) FRAGMENT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10626151" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Heavy-chain diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1566748" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Mu-heavy chain disease: presentation as a benign monoclonal gammopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7819086" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : First report of fludarabine in gamma-heavy chain disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24683718" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The heavy chain diseases: clinical and pathologic features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9285150" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Cast nephropathy in mu heavy chain disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15203869" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Mu-heavy chain disease associated with systemic amyloidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5542148" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Ultrastructural and immunofluorescence studies of the cells associated with mu-chain disease.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
